logo
ACHV: Achieve's Busy Day

ACHV: Achieve's Busy Day

Yahoo06-07-2025
By John Vandermosten, CFA
NASDAQ:ACHV
READ THE FULL ACHV RESEARCH REPORT
Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation.
Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26.
NDA Submission
Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end.
Commercialization Partnership
Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies.
Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group.
The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights.
Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities.
Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate.
Public Offering
On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing.
ORCA-OL Safety Trial
Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1]
Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology.
Milestones
Development of cytisinicline product label for smoking cessation – 1H:25
Completion of six months of ORCA-OL safety data for 300 subjects – January 2025
Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025
Attendance at Barclays Healthcare Conference, Miami – March 2025
Selection of 3rd party logistics partner – 2Q:25
NDA Submission – 2Q:25
FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25
Launch of Phase III vaping trial – 1H:26
FDA target action date for cytisinicline NDA – 1H:26
Launch of cytisinicline – 3Q:26
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer .
________________________
[1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jensen Huang Says He's Created More Billionaires Than Any CEO: 'Don't Feel Sad For Anybody At My Layer'
Jensen Huang Says He's Created More Billionaires Than Any CEO: 'Don't Feel Sad For Anybody At My Layer'

Yahoo

time12 minutes ago

  • Yahoo

Jensen Huang Says He's Created More Billionaires Than Any CEO: 'Don't Feel Sad For Anybody At My Layer'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As the Donald Trump administration unveiled its AI policy plan, Nvidia Corp. (NASDAQ:NVDA) CEO Jensen Huang joined top Silicon Valley figures to weigh in on the cutthroat battle for AI talent and compensation during a live podcast in Washington, D.C. What Happened: Earlier this week, appearing on the All-in podcast alongside venture capitalists Chamath Palihapitiya and Jason Calacanis, Huang pushed back on concerns about executive-level compensation amid billion-dollar offers for AI researchers. During the conversation, Palihapitiya raised the point that AI researchers were being offered unprecedented contracts—one reportedly as high as $1 billion over four years from Meta Platforms Inc. (NASDAQ:META). He asked why similar valuations weren't seen at the CEO level, despite their role in enabling breakthroughs. "First of all, I've created more billionaires on my management team than any CEO in the world. They're doing just fine," Huang said. "Don't feel sad for anybody at my layer." Trending: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— Huang also underscored the efficiency of small, well-funded teams in AI. "The impact of 150 or so AI researchers can probably create, with enough funding, an OpenAI. There's something about the elegance of small teams," he said. Later, Calacanis added levity, teasing Huang about rumors of a secret stash of stock options. "Somebody told me you just drop RSUs on people if they do a great job," he joked. "That's nuts," Huang responded, adding, "I review everyone's comp myself ... and I 100% of the time increase opex because you take care of people and everything else takes care of itself." Why It's Important: The discussion came during the Trump administration's unveiling of its AI Action Plan, a strategic initiative backed by a new wave of Silicon Valley. The fierce competition for AI talent has driven record compensation and high-profile hires across companies like Meta, Microsoft Corp. (NASDAQ:MSFT), OpenAI and Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind—often eclipsing executive salaries and reshaping the power dynamics in the tech world. Earlier this week, Alphabet CEO Sundar Pichai also dismissed concerns over an AI talent exodus, stating the company remains strong in attracting and retaining top AI experts. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. Photo courtesy: jamesonwu1972 On This article Jensen Huang Says He's Created More Billionaires Than Any CEO: 'Don't Feel Sad For Anybody At My Layer' originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CORRECTING and REPLACING Zip Marks Fifth Anniversary with New Offices in San Francisco and New York
CORRECTING and REPLACING Zip Marks Fifth Anniversary with New Offices in San Francisco and New York

Yahoo

time12 minutes ago

  • Yahoo

CORRECTING and REPLACING Zip Marks Fifth Anniversary with New Offices in San Francisco and New York

Agentic Procurement Orchestration Leader Doubles Office Footprint Amid Explosive Growth, Surpasses Hundreds of Billions in Processed Requests SAN FRANCISCO, July 26, 2025--(BUSINESS WIRE)--Please replace the release dated July 24, 2025, with the following corrected version due to multiple revisions. The updated release reads: ZIP MARKS FIFTH ANNIVERSARY WITH NEW OFFICES IN SAN FRANCISCO AND NEW YORK Agentic Procurement Orchestration Leader Doubles Office Footprint Amid Explosive Growth, Surpasses Hundreds of Billions in Processed Requests Zip, the world's leading agentic procurement orchestration platform, today celebrated its fifth anniversary by unveiling expanded offices in San Francisco and New York to accommodate rapid workforce growth driven by unprecedented enterprise adoption. The company has grown from 250 to over 500 employees in the past year alone while securing Global 2000 customers across every major industry. Five years ago, Zip's founders chose to tackle procurement – hardly the most glamorous corner of technological innovation. While others chased trendy markets, Zip focused on the overlooked but critical process of how companies buy what they need. Few shared their vision. Then the world changed. Supply chain disruptions, inflation, and tariffs turned procurement from a back-office afterthought into a C-suite priority. What Zip had been quietly building suddenly became every CEO's top concern. That early vision, combined with five years of relentless innovation and AI leadership, explains why global giants from OpenAI to Discover are choosing Zip to transform their operations. "Over the past five years, we've built something remarkable – a product so sticky that we've maintained 100% retention across our strategic enterprise customers," said Rujul Zaparde, Co-founder and CEO of Zip. "The fact that Fortune 500 companies across financial services, telecommunications, healthcare, defense, and retail are choosing a five-year-old company over established vendors speaks to how fundamentally we've reimagined procurement. We've processed over hundreds of billions in total purchasing request volume since our founding five years ago and we've barely scratched the surface of the global opportunity." From Zero to $2.2 Billion: Five Years of Unprecedented Growth Zip's journey from startup to enterprise standard represents one of the fastest value creation stories in enterprise software history. In October 2024, the company secured $190 million in Series D funding at a $2.2 billion valuation, marking the largest investment in procurement technology in over two decades and validating Zip's position as the category leader. Since its founding in 2020, Zip has achieved milestones that typically take enterprise software companies decades: Customer Momentum: Trusted by hundreds of global enterprises including AMD, Anthropic, Canva, Coinbase, Discover, Lyft, Northwestern Mutual, OpenAI, Pinterest, Reddit, Sephora, and Snowflake Financial Impact: Generated $4.4 billion in customer savings, with companies averaging 3.6% reduction in total spend savings and 25% in productivity gains Product Innovation: Introduced intake to the world, pioneered orchestration, and launched the industry's first agentic AI suite with 50+ procurement agents. Platform has delivered 4.6 million AI insights and achieved unprecedented engagement for an enterprise software platform with 14 million customer comments Doubling Down on Talent and Geographic Expansion To support its trajectory, Zip is hiring aggressively across all markets while significantly expanding its physical footprint: San Francisco: New headquarters doubles office space to 75,000 square feet, housing 200+ employees from top universities like Stanford and MIT, and companies like Meta, Airbnb, and Scale. The expansion reaffirms Zip's commitment to San Francisco as its global headquarters, investing in the city's downtown revitalization New York: Expanding beyond co-working to establish a permanent Manhattan headquarters, positioning Zip closer to financial services and media giants Global Reach: 60+ employees across EMEA, with continued expansion in London The company has grown from approximately 250 employees to over 500 in the past year, hiring 100+ people per quarter, with spending heavily weighted toward R&D. Five Years of Relentless Innovation Zip's trajectory from introducing intake to pioneering agentic procurement orchestration showcases the company's ability to anticipate and shape market needs: 2020: Founded with a vision to fix broken procurement processes; introduced intake and procurement orchestration to the world, transforming how companies start the procurement process 2021: Revolutionized workflows by launching dynamic approvals and integrating with 25+ enterprise systems including ERPs, CLMs, and GRC platforms 2022: Expanded beyond intake to full Procure-to-Pay capabilities, enabling end-to-end procurement orchestration 2023: Became the first procurement platform to embed generative AI, delivering millions of AI-powered insights to customers 2024: Launched the Integration Platform enabling rapid enterprise deployments; established the Zip AI Lab following landmark Series D funding 2025: Introduced Agentic Procurement Orchestration; unveiled suite of 50+ specialized AI agents that autonomously handle complex procurement tasks from tariff analysis to contract reviews "Five years ago, we introduced intake to the world. We scaled orchestration. Now, we're shaping the agentic future with 50+ AI agents that are redefining what procurement is capable of," added Lu Cheng, Zip Co-founder and CTO. "The most exciting part? We're just getting started." This fall, Zip will host Zip Forward 2025 at San Francisco's Yerba Buena Center for the Arts, where 750+ procurement and finance leaders will gather under the theme 'Agents of Change.' To request an invitation, please visit About Zip Zip is the world's leading agentic procurement orchestration platform, empowering businesses to accelerate the procurement process, mitigate risk, and drive growth by offering a single front door to unify the teams, tasks, and tools involved in working with suppliers. With Zip, businesses can maximize employee adoption of purchasing policies and increase spend visibility and control. As the leading solution for optimizing business spend, Zip's AI-powered platform is trusted by hundreds of leading enterprises worldwide, including AMD, Anthropic, Coinbase, Discover, Dollar Tree, Instacart, Invesco, Lyft, Northwestern Mutual, Prudential, Reddit, Sephora, and Snowflake to maximize the ROI of every dollar. To learn more, visit View source version on Contacts chrysta@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Trump's EPA Reportedly Wants to Remove Limits on Tailpipe Emissions
Trump's EPA Reportedly Wants to Remove Limits on Tailpipe Emissions

Yahoo

time12 minutes ago

  • Yahoo

Trump's EPA Reportedly Wants to Remove Limits on Tailpipe Emissions

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new draft plan is reportedly going to unwind the EPA's ruling that greenhouse gases are a public health issue. If passed, the federal agency's ability to enforce restrictions on automakers could be limited in the future. The plan would overturn official EPA policy that has been in place since 2009. A newly drafted plan from the Environmental Protection Agency (EPA), said to be days away from going public, aims to strip the agency's ability to limit greenhouse gases. According to reporting from the New York Times, the draft proposal rescinds a 2009 declaration that carbon dioxide and methane emissions are hazardous to public health. If verified and passed, such a proposal presents further headwinds to EV adoption and also removes limits on tailpipe emissions. The ruling would also affect industrial pollution, but as far as the automotive industry is concerned, it would remove carbon emission limitations as a target for automakers. With fines for CAFE (Corporate Average Fuel Economy) violations largely eliminated and federal rebates for EV purchases gone, this new change could continue to change the course of domestic car manufacturing. Long-term, such a change would limit the EPA's authority to enforce rules aimed at limiting climate change. The proposed draft is said not to argue with the science regarding greenhouse gas emissions, but rather it states that the EPA has legally overstepped its authority. It seeks to limit the EPA's ability to legislate except in specific circumstances. There are several steps to be taken before such a change occurs, not least of which are various legal hurdles. If enacted, the new plan would almost certainly face challenges from various sources. It also has to weather some form of public review. It took two years for the EPA to officially label greenhouse gases as a public health issue after a 2007 Supreme Court ruling that they were pollutants under the Clean Air Act. Unwinding this finding may take a similarly long timeline. If you are in the automaking business, however, it's fairly straightforward to see which way the winds are blowing. For the near future, investing in combustion-powered transportation is likely to be the safe bet. You Might Also Like Car and Driver's 10 Best Cars through the Decades How to Buy or Lease a New Car Lightning Lap Legends: Chevrolet Camaro vs. Ford Mustang!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store